Original Publication Date: 13 December, 2013
Publication / Source: Breast Cancer Management
Authors: Daniel Dang & Yan Peng
p53 and p16 are both tumor suppressors. This article summarizes the current investigation status on their roles and interaction in triple-negative breast cancer (TNBC) to explore their potential as prognostic, predictive and therapeutic targets. There is significant evidence implicating that p53 mutation as a driver plays an important role in tumorigenesis and progression of TNBC. p53 mutations are more frequently observed in TNBCs compared with ER-positive breast cancers. The presence of a p53 mutation is associated with poorer prognosis in TNBC patients. The status of p53 protein expression divides TNBCs into two biologically distinct subgroups (p53-positive vs p53-negative); p53-positive tumors have more aggressive behavior. p53 has clinical prognostic utility and is a promising target candidate for directed therapy for TNBC patients. p16 appears to play a significant role in tumorigenesis of TNBC through the Rb/p16 dysfunction pathway.